Allscripts Healthcare Solutions Inc MDRX

NAS: MDRX | ISIN: US01988P1084   26/04/2024
7,960 USD (+0,13%)
(+0,13%)   26/04/2024

MDRX Investors Have Opportunity to Lead Veradigm Inc. Securities Fraud Lawsuit

LOS ANGELES, Jan. 11, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Veradigm Inc. ("Veradigm" or the "Company") (NASDAQ: MDRX).

Class Period: February 26, 2021December 7, 2023
Lead Plaintiff Deadline: January 22, 2024

If you wish to serve as lead plaintiff of the Veradigm lawsuit, you can submit your contact information at www.glancylaw.com/cases/Veradigm-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Veradigm had overstated its historical revenues by at least $20 million; (2) Veradigm had artificially inflated its revenue by recording duplicate transactions, among other things, over a more than two-year period; (3) Veradigm had artificially inflated its earnings and margins and materially misrepresented demand for the Company's products and services during the Class Period; (4) Veradigm had failed to maintain effective internal controls over its financial reporting; (5) Veradigm had failed to comply with Generally Accepted Accounting Principles ("GAAP") regarding appropriate revenue recognition practices; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mdrx-investors-have-opportunity-to-lead-veradigm-inc-securities-fraud-lawsuit-302032179.html

SOURCE Glancy Prongay & Murray LLP

Mijn selecties